Mycobacterium Abscessus 폐질환의 치료

키워드

참고문헌 (64)

1. Griffith DE, "An official ATS", IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, 2007, pp.175, 367~416
2. Honda JR, "Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches", Front Microbiol, 9, pp.2029~ (2018)
3. Jeon D, "Infection source and epidemiology of nontuberculous mycobacterial lung disease", Tuberc Respir Dis(Seoul), 82, pp.94~101 (2019)
4. Lee H, "Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016", Emerg Infect Dis, 25, pp.569~572 (2019)
5. Yoon HJ, "Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea", BMC Infect Dis, 17, pp.432~ (2017)
6. Koh WJ, "Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea", Chest, 129, pp.341~348 (2006)
7. 권용수, "Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease", Journal of Korean Medical Science, 31(5), pp.649~659 (2016), 대한의학회
8. Ko RE, "Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015", J Korean Med Sci, 33, pp.e65~ (2018)
9. Pasipanodya JG, "Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence", Antimicrob Agents Chemother, 61, pp.e01206~ (2017)
10. Diel R, "Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease : a systematic review and meta-analysis", Chest, 152, pp.120~142 (2017)
11. Kwak N, "Mycobacterium abscessus pulmonary disease : individual patient data metaanalysis", Eur Respir J, 54, pp.1801991~ (2019)
12. Moon SM, "Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease", Respir Med, 151, pp.1~7 (2019)
13. Brown-Elliott BA, "Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria", Clin Microbiol Rev, 15, pp.716~746 (2002)
14. Moore M, "An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region;report of a case with a study of the organism, Mycobacterium abscessus, n. sp", J Invest Dermatol, 20, pp.133~169 (1953)
15. Adékambi T, "rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov", Int J Syst Evol Microbiol, 56, pp.133~143 (2006)
16. Leao SC, "Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus", Int J Syst Evol Microbiol, 61, pp.2311~2313 (2011)
17. Lee MR, "Mycobacterium abscessus complex infections in humans", Emerg Infect Dis, 21, pp.1638~1646 (2015)
18. Tortoli E, "Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov", Int J Syst Evol Microbiol, 66, pp.4471~4479 (2016)
19. Tortoli E, "Mycobacterium abscessus, a taxonomic puzzle", Int J Syst Evol Microbiol, 68, pp.467~469 (2018)
20. Koh WJ, "Advances in the management of pulmonary disease due to Mycobacterium abscessus complex", Int J Tuberc Lung Dis, 18, pp.1141~1148 (2014)
21. Morimoto K, "Clinico-microbiological analysis of 121 patients with pulmonary Mycobacteroides abscessus complex disease in Japan-An NTM-JRC study with RIT", Respir Med, 145, pp.14~20 (2018)
22. Nash KA, "A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae", Antimicrob Agents Chemother, 53, pp.1367~1376 (2009)
23. van Ingen J, "Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria", Drug Resist Updat, 15, pp.149~161 (2012)
24. Koh WJ, "Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus", Am J Respir Crit Care Med, 183, pp.405~410 (2011)
25. Choi GE, "Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance", Am J Respir Crit Care Med, 186, pp.917~925 (2012)
26. Brown-Elliott BA, "Utility of sequencing the erm (41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs", J Clin Microbiol, 53, pp.1211~1215 (2015)
27. Choi H, "Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease", Diagn Microbiol Infect Dis, 90, pp.293~295 (2018)
28. Clinical Laboratory Standards Institute (CLSI), "M62 susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes" (2011), Clinical Laboratory Standards Institute
29. Koh WJ, "Oral macrolide therapy following short-term combination antibiotic treatment of Mycobacterium massiliense lung disease", Chest, 150, pp.1211~1221 (2016)
30. Jarand J, "Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease", Clin Infect Dis, 52, pp.565~571 (2011)
31. Jeon K, "Antibiotic treatment of Mycobacterium abscessus lung disease : a retrospective analysis of 65 patients", Am J Respir Crit Care Med, 180, pp.896~902 (2009)
32. Lyu J, "Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs", Respir Med, 105, pp.781~787 (2011)
33. Lyu J, "A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease", Respir Med, 108, pp.1706~1712 (2014)
34. Park J, "Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense", Clin Infect Dis, 64, pp.301~308 (2017)
35. Koh WJ, "Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease", Clin Infect Dis, 64, pp.309~316 (2017)
36. Floto RA, "US cystic fibrosis foundation and european cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis", Thorax, 71(Suppl 1), pp.i1~i22 (2016)
37. Haworth CS, "British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease(NTM-PD)", Thorax, 72, pp.ii1~ii64 (2017)
38. Clinical Laboratory Standards Institute (CLSI), "M62 performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 1st ed", Clinical Laboratory Standards Institute, ~ (2018)
39. Zimmermann P, "The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms", Front Immunol, 9, pp.302~ (2018)
40. Crosbie PA, "Long-term macrolide therapy in chronic inflammatory airway diseases", Eur Respir J, 33, pp.171~181 (2009)
41. Choi H, "Clinical characteristics and treatment outcomes of patients with acquired macrolideresistant Mycobacterium abscessus lung disease", Antimicrob Agents Chemother, 61, pp.e01146~ (2017)
42. 이승헌, "The Drug Resistance Profile of Mycobacterium abscessus Group Strains from Korea", Annals of Laboratory Medicine, 34(1), pp.31~37 (2014), 대한진단검사의학회
43. Cho EH, "Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens", Diagn Microbiol Infect Dis, 93, pp.107~111 (2019)
44. Kim SY, "The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea", Diagn Microbiol Infect Dis, 81, pp.107~111 (2015)
45. Olivier KN, "Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease", Ann Am Thorac Soc, 11, pp.30~35 (2014)
46. Yagi K, "The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases", BMC Infect Dis, 17, pp.558~ (2017)
47. Jhun BW, "Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease", Antimicrob Agents Chemother, 62, pp.e00011~ (2018)
48. Olivier KN, "Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease", Am J Respir Crit Care Med, 195, pp.814~823 (2017)
49. Griffith DE, "Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study", Am J Respir Crit Care Med (2018)
50. Shirley M, "Amikacin liposome inhalation suspension : a review in Mycobacterium avium complex lung disease", Drugs, 79, pp.555~562 (2019)
51. Wallace RJ Jr, "Comparison of the in vitro activity of the glycylcycline tigecycline(formerly GAR-936)with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria", Antimicrob Agents Chemother, 46, pp.3164~3167 (2002)
52. Ferro BE, "Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease", Antimicrob Agents Chemother, 60, pp.2895~2900 (2016)
53. Wallace RJ Jr, "Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections", J Antimicrob Chemother, 69, pp.1945~1953 (2014)
54. Clinical Laboratory Standards Institute (CLSI), "M62 Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed", Clinical Laboratory Standards Institute, ~ (2018)
55. "WHO consolidated guidelines on drug-resistant tuberculosis treatment" (2019)[URL]
56. Yang B, "Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease", Antimicrob Agents Chemother, 61, pp.e02052~ (2017)
57. Martiniano SL, "Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial Infection", Chest, 152, pp.800~809 (2017)
58. Shen GH, "High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria", Int J Antimicrob Agents, 35, pp.400~404 (2010)
59. van Ingen J, "In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease", Antimicrob Agents Chemother, 56, pp.6324~6327 (2012)
60. Winthrop KL, "The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease", Eur Respir J, 45, pp.1177~1179 (2015)
61. "Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the american thoracic society was approved by the board of directors, march 1997. Medical section of the american lung association", Am J Respir Crit Care Med, 156, pp.S1~S25 (1997)
62. Ferro BE, "Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin", Antimicrob Agents Chemother, 60, pp.1097~1105 (2016)
63. Mitchell JD, "Surgical management of pulmonary mycobacterial disease", Semin Respir Crit Care Med, 39, pp.392~398 (2018)
64. Kang HK, "Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease", BMC Infect Dis, 15, pp.76~ (2015)

관련 논문AI추천